Fascin-1 是肾上腺皮质癌中与肿瘤侵袭性相关的新型预后生物标志物
该研究评估了肌动蛋白捆绑蛋白 fascin-1(FSCN1)在肾上腺皮质肿瘤中的诊断和预后价值。在 37 例恶性/37 例良性肾上腺皮质肿瘤的本地系列及两个独立 ACC 验证队列中,FSCN1 免疫组化检测虽诊断效力低,但为独立预后因素,并在两个独立队列中证实其稳健预后效力。FSCN1 与 SF-1 正相关,且在 SF-1 剂量增加时促进人 ACC 细胞系侵袭。
要点
- FSCN1 在 ACC 中为独立预后因素,可细化分期和 Ki67 的预后信息。
- FSCN1 与 SF-1 正相关,在晚期和侵袭性 Weiss 评分参数肿瘤中表达更高。
- FSCN1 仅在 SF-1 剂量增加时促进 ACC 细胞侵袭,可能为治疗靶点。
核心结论
- FSCN1 是 ACC 的新型独立预后标志物,可能作为阻断肿瘤扩散的潜在治疗靶点。
研究设计与样本
- 研究包含 Careggi 大学医院 37 例恶性/37 例良性肾上腺皮质肿瘤本地系列,以及两个独立 ACC 验证队列(Cochin、TCGA)。
- FSCN1 表达通过免疫组化、Western blot 和定量 RT-PCR 在 ACC 标本中定量。
主要发现
- 在 Florence ACC 系列中,FSCN1 免疫组化检测诊断效力低,但为独立预后因素,可细化分期和 Ki67 标记指数的结果。
- FSCN1 水平的稳健预后效力在两个独立 ACC 队列中得到进一步证实。
- FSCN1 与类固醇生成因子-1(SF-1)呈正相关,两者在晚期 ACC 及至少一个与侵袭性相关的 Weiss 评分参数肿瘤中表达显著更高。
- 在 SF-1 剂量增加的情况下,FSCN1 促进人 ACC 细胞系中的细胞侵袭。
临床怎么用
- FSCN1 免疫组化检测可用于 ACC 患者预后分层,辅助分期和 Ki67 评估。
- FSCN1 高表达提示肿瘤侵袭性更强,可能需更密切随访。
局限性
- FSCN1 的诊断效力低,不适用于肾上腺皮质肿瘤的良恶性鉴别诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Novel tumor markers are urgently needed to better stratify adrenocortical cancer (ACC) patients and improve therapies for this aggressive neoplasm. OBJECTIVE: To assess the diagnostic and prognostic value of the actin-bundling protein fascin-1 (FSCN1) in adrenocortical tumors. DESIGN, SETTING AND PARTICIPANTS: A local series of 37 malignant/37 benign adrenocortical tumors at Careggi University Hospital and two independent validation ACC cohorts (Cochin, TCGA) from the European Network for the Study of Adrenal Tumors were studied. MAIN OUTCOME MEASURES: FSCN1 expression was quantified by immunohistochemistry, Western blot and quantitative RT-PCR in ACC specimens; overall and disease-free survival associated with FSCN1 expression were assessed by Kaplan-Meier analysis and compared with that of Ki67 labeling index and tumor stage. RESULTS: Despite the low diagnostic power, in the Florence ACC series, FSCN1 immunohistochemical detection appeared as an independent prognostic factor, also refining results obtained with staging and Ki67 labeling index. The robust prognostic power of FSCN1 levels was further confirmed in two independent ACC cohorts. A positive correlation was found between FSCN1 and steroidogenic factor-1 (SF-1), with a substantially higher expression of both factors in ACCs at advanced stages and with at least one of the three Weiss score parameters associated with invasiveness. Moreover, we demonstrated FSCN1 role in promoting cell invasion in a human ACC cell line only in the case of increased SF-1 dosage. CONCLUSIONS: These findings show that FSCN1 is a novel independent prognostic marker in ACC and may serve as a potential therapeutic target to block tumor spread.
引用
- Poli G, Ruggiero C, Cantini G, et al. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2019. PMID: 30476173. doi:10.1210/jc.2018-01717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。